# Azelastine Allergen Chamber - Onset of Action Study

> **NCT06126952** · PHASE2 · COMPLETED · sponsor: **MEDA Pharma GmbH & Co. KG** · enrollment: 84 (actual)

## Conditions studied

- Seasonal Allergic Rhinitis

## Interventions

- **DRUG:** Treatment A: Azelastine hydrochloride 0.15% nasal spray (Azelair)
- **DRUG:** Treatment B: Placebo (Azelastine 0.15% vehicle) nasal spray
- **DRUG:** Treatment C: Ryaltris (Active Control) - mometasone furoate monohydrate and olopatadine hydrochloride nasal spray

## Key facts

- **NCT ID:** NCT06126952
- **Lead sponsor:** MEDA Pharma GmbH & Co. KG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-30
- **Primary completion:** 2024-02-23
- **Final completion:** 2024-03-18
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2024-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06126952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06126952, "Azelastine Allergen Chamber - Onset of Action Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06126952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*